About the new version of recommendations for the correction of dyslipidemia in order to prevent atherosclerosis and its complications

Abstract

In this issue, the reader is presented with a new version of the Russian recommendations for the correction of dyslipidemia, prepared by experts from the Russian National Society of Atherosclerosis, the Russian Society of Cardiology and the Russian Society of Endocrinologists. The VI version of the Recommendations was released in 2017 and, it would seem, a short time has passed to offer a new version. However, there are good reasons for this revision. In 2019, the European Society of Cardiology and the European Society of Atherosclerosis released a new version for the correction of dyslipidemia, which reflects fundamentally new positions on target lipid levels. and lipoproteins, as measured by cardiovascular risk. New approaches to the treatment of dyslipidemia have appeared in the form of prescribing monoclonal antibodies to proprotein-convertase subtilisin / kexin type 9 (PCSK9). Finally, significant changes have occurred in the features of correction of dyslipidemia (DLP) in different groups of patients, primarily in patients with diabetes mellitus (DM), familial hypercholesterolemia, the elderly, women and other categories of patients.